Discovery and Structure–Activity Relationship of a Ryanodine Receptor 2 Inhibitor

IF 1.5 4区 医学 Q4 CHEMISTRY, MEDICINAL
Ryosuke Ishida, Xi Zeng, Nagomi Kurebayashi, Takashi Murayama, Shuichi Mori, Hiroyuki Kagechika
{"title":"Discovery and Structure–Activity Relationship of a Ryanodine Receptor 2 Inhibitor","authors":"Ryosuke Ishida, Xi Zeng, Nagomi Kurebayashi, Takashi Murayama, Shuichi Mori, Hiroyuki Kagechika","doi":"10.1248/cpb.c24-00114","DOIUrl":null,"url":null,"abstract":"</p><p>Ryanodine receptor 2 (RyR2) is a large Ca<sup>2+</sup>-release channel in the sarcoplasmic reticulum (SR) of cardiac muscle cells. It serves to release Ca<sup>2+</sup> from the SR into the cytosol to initiate muscle contraction. RyR2 overactivation is associated with arrhythmogenic cardiac disease, but few specific inhibitors have been reported so far. Here, we identified an RyR2-selective inhibitor <b>1</b> from the chemical compound library and synthesized it from glycolic acid. Synthesis of various derivatives to investigate the structure–activity relationship of each substructure afforded another two RyR2-selective inhibitors <b>6</b> and <b>7</b>, among which <b>6</b> was the most potent. Notably, compound <b>6</b> also inhibited Ca<sup>2+</sup> release in cells expressing the RyR2 mutants R2474S, R4497C and K4750Q, which are associated with cardiac arrhythmias such as catecholaminergic polymorphic ventricular tachycardia (CPVT). This inhibitor is expected to be a useful tool for research on the structure and dynamics of RyR2, as well as a lead compound for the development of drug candidates to treat RyR2-related cardiac disease.</p>\n<p></p>\n<img alt=\"\" src=\"https://www.jstage.jst.go.jp/pub/cpb/72/4/72_c24-00114/figure/72_c24-00114.png\"/>\n<span style=\"padding-left:5px;\">Fullsize Image</span>","PeriodicalId":9773,"journal":{"name":"Chemical & pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical & pharmaceutical bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1248/cpb.c24-00114","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Ryanodine receptor 2 (RyR2) is a large Ca2+-release channel in the sarcoplasmic reticulum (SR) of cardiac muscle cells. It serves to release Ca2+ from the SR into the cytosol to initiate muscle contraction. RyR2 overactivation is associated with arrhythmogenic cardiac disease, but few specific inhibitors have been reported so far. Here, we identified an RyR2-selective inhibitor 1 from the chemical compound library and synthesized it from glycolic acid. Synthesis of various derivatives to investigate the structure–activity relationship of each substructure afforded another two RyR2-selective inhibitors 6 and 7, among which 6 was the most potent. Notably, compound 6 also inhibited Ca2+ release in cells expressing the RyR2 mutants R2474S, R4497C and K4750Q, which are associated with cardiac arrhythmias such as catecholaminergic polymorphic ventricular tachycardia (CPVT). This inhibitor is expected to be a useful tool for research on the structure and dynamics of RyR2, as well as a lead compound for the development of drug candidates to treat RyR2-related cardiac disease.

Abstract Image Fullsize Image
Ryanodine 受体 2 抑制剂的发现与结构活性关系
Ryanodine 受体 2(RyR2)是心肌细胞肌浆网(SR)中的一个大型 Ca2+ 释放通道。它的作用是将 Ca2+ 从肌浆网释放到细胞质中,从而启动肌肉收缩。RyR2 过度激活与心律失常性心脏病有关,但迄今为止很少有特异性抑制剂的报道。在此,我们从化合物库中发现了一种 RyR2 选择性抑制剂 1,并用乙醇酸将其合成。通过合成各种衍生物来研究每种亚结构的结构-活性关系,我们又得到了两种 RyR2 选择性抑制剂 6 和 7,其中 6 的抑制效果最好。值得注意的是,化合物 6 还能抑制表达 RyR2 突变体 R2474S、R4497C 和 K4750Q 的细胞中 Ca2+ 的释放,这些突变体与儿茶酚胺能多形性室性心动过速(CPVT)等心律失常有关。这种抑制剂有望成为研究 RyR2 结构和动力学的有用工具,以及开发治疗 RyR2 相关心脏疾病候选药物的先导化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.20
自引率
5.90%
发文量
132
审稿时长
1.7 months
期刊介绍: The CPB covers various chemical topics in the pharmaceutical and health sciences fields dealing with biologically active compounds, natural products, and medicines, while BPB deals with a wide range of biological topics in the pharmaceutical and health sciences fields including scientific research from basic to clinical studies. For details of their respective scopes, please refer to the submission topic categories below. Topics: Organic chemistry In silico science Inorganic chemistry Pharmacognosy Health statistics Forensic science Biochemistry Pharmacology Pharmaceutical care and science Medicinal chemistry Analytical chemistry Physical pharmacy Natural product chemistry Toxicology Environmental science Molecular and cellular biology Biopharmacy and pharmacokinetics Pharmaceutical education Chemical biology Physical chemistry Pharmaceutical engineering Epidemiology Hygiene Regulatory science Immunology and microbiology Clinical pharmacy Miscellaneous.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信